Evaluating tirzepatide reduces weight and improves glycaemic control in individuals with partial lipodystrophy, indicating potential benefits.
In patients with partial lipodystrophy, tirzepatide use resulted in substantial statistically significant reductions in weight, glycaemic control, serum triglycerides and daily insulin requirement. We recommend further prospective studies to support these findings and to evaluate its impact earlier in the course of the disorder.
No takes yet. Share an insight, caveat, or question.
Mandour et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: